2015 51th ASCO Annual Meeting - účast ČR

Gastrointestinal (Colorectal) Cancer

Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases.

Autoři: Cecile Rose T. Vibat; MUDr. Vlada Melniková, Ph.D.; RNDr. Marek Minárik, Ph.D.; Barbora Belšánová; Saege Hancock; Latifa Hassaine; Errin Samuelsz; Timothy T. Lu; Mark G. Erlander, M.D.; RNDr. Lucie Benešová, Ph.D.
Číslo abstraktu: 3594
Kategorie: Kolorektální karcinom

Gastrointestinal (Noncolorectal) Cancer

Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).

Autoři: M.D. Charles S. Fuchs, MPH; Josep Tabernero, MD; MUDr. Jiří Tomášek, Ph.D.; M.D. Ian Chau; prof. MUDr. Bohuslav Melichar, Ph.D.; Prof. Dr. Howard Safran; Mustapha Ali Tehfe; Dr. Filip Dumitru; M.D. Eldar Topuzov, Ph.D.; Dr. Luis (Alberto) Schlittler; Dr. Anghel Adrian Udrea; Dr. William Campbell; Dr. Stephen Brincat; MD Michael Emig; Symantha A. Melemed, Ph.D.; Rebecca R. Hozak; Prof. M.D. David R. Ferry, Ph.D.; William Caldwell; Prof. MD Jaffer A. Ajani
Číslo abstraktu: 4029
Kategorie: Gastrointestinální nádory

Genitourinary (Nonprostate) Cancer

Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).

Autoři: MD Robert J. Motzer; MD Thomas Hutson; Hilary Glen, PhD, MSc, MRCP, MBCHB; MD Dror Michaelson, Ph.D.; Ass Prof., Dr. Ana M. Molina; prof. Timothy Eisen; prof. dr hab. n. med. Jacek Jassem; MD Jakub Zolnierek; Dr. Pablo Maroto; Begona Mellado; prof. MUDr. Bohuslav Melichar, Ph.D.; MUDr. Jiří Tomášek, Ph.D.; Han-Joo Kim; Karen Wood; MD Corina Dutcus; MD James M. G. Larkin
Číslo abstraktu: 4506
Kategorie: Genitourinární nádory

Leukemia, Myelodysplasia, and Transplantation

Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study

Autoři: M.D. Asher Alban Akmal Chanan-Khan; MD Paula Cramer; prof. MUDr. Fatih Demirkan; Dr. Graeme Fraser; Dr. Rodrigo Santucci Silva; MD Halyna Pylypenko; M.D. Sebastian Grosicki; MD Ann Janssens; M.D. Alexander S. Pristupa, Ph.D.; prof. MUDr. Jiří Mayer, CSc.; Marie-Sarah Dilhuydy; Dr. Javier Loscertales; Dr. Nancy L. Bartlett, MD; Dr. Abraham Avigdor; prof. Simon A. Rule; Steven Sun; Michelle Mahler; Mariya Salman; Angela J. Howes; Prof. MD Michael Hallek
Číslo abstraktu: LBA7005
Kategorie: Maligní lymfomy a leukémie

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).

Autoři: MD Ruben A. Mesa; MD Miklós Egyed, PhD.; MD Anita Szőke, Ph.D.; M.D. Alexander Suvorov; Dr. Andrew Perkins; prof. MUDr. Jiří Mayer, CSc.; Dr. Peter Ganly; Dr. Eric Jourdan; MD Harry C. Schouten, PhD; Dr. Patrizia Tosi; MD Charles Michael Farber, PhD, FACP; Dr. Pierre Zachee; Prof. MD Christof Scheid, Ph.D.; MD James P. Dean, PhD; Paul Cernohous; Dr. Jyoti Nangalia; Dr. Jean-Jacques Kiladjian; MD Alessandro M. Vannucchi; prof. Adam Mead, MRCP FRCPath ; Claire N. Harrison
Číslo abstraktu: LBA7006
Kategorie: Maligní lymfomy a leukémie

Lymphoma

GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

Autoři: Laurie H. Sehn; Dr. Neil Sun Chua; prof. MUDr. Jiří Mayer, CSc.; Clinical Assistant Professor Gregory Scott Dueck; Prof. MUDr. Marek Trněný, CSc.; MD Krimo (Kamal) Bouabdallah; MD Nathan Hale Fowler; Vincent Delwail; MD Oliver W. Press, Ph.D.; MD Gilles Andre Salles, PhD; M.D. John G. Gribben, DSC, FMedSci; Dr. Anne Lennard, MBBS (Hons), FRCP, FRCPath; Pieternella J. Lugtenburg; Natalie Franklin; Elisabeth Wassner Fritsch; Guenter Fingerle-Rowson; MD Bruce D. Cheson, BA
Číslo abstraktu: LBA8502
Kategorie: Maligní lymfomy a leukémie

Lymphoma and Plasma Cell Disorders

AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab.

Autoři: Prof. M.D. John P. Leonard; M.D. John G. Gribben, DSC, FMedSci; Prof. MUDr. Marek Trněný, CSc.; M.D. Phillip Scheinberg; MD Kensei Tobinai, Ph.D.; MD Nathan Hale Fowler; Nurgul Kilavuz; Pierre Fustier; MD Barbara Amoroso, Ph.D.
Číslo abstraktu: TPS8603
Kategorie: Maligní lymfomy a leukémie

Myeloma

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Autoři: Prof. MD Sagar Lonial; Meletios Athanasios Dimopoulos, MD; MD Antonio P. Palumbo; Darrell J. White; M.D. Sebastian Grosicki; Prof.MUDr. Ivan Špička, PhD; Adam Walter-Croneck; Prof. MD Philippe Moreau; MD Maria-Victoria Mateos, PhD; Hila Magen-Nativ; prof. MD Andrew Belch; MD Donna E. Reece, FRCPC; prof. MD Meral Beksac; MD Masafumi Taniwaki; MD Christoph Röllig; Anil K. Singhal; Jessica Katz; MD Eric W. Bleickardt; Valeriet Poulart; MD Paul Gerard Guy Richardson
Číslo abstraktu: 8508
Kategorie: Mnohočetný myelom

Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.

Autoři: Meletios Athanasios Dimopoulos, MD; prof. MUDr. Roman Hájek, CSc.; Prof. Dr. med. Hartmut Goldschmidt; MD Thierry Facon; Prof. MD Heinz Ludwig; Douglas E. Joshua; Prof. MD Philippe Moreau; M.D. Albert Oriol; MD Antonio P. Palumbo; prof. MUDr. Luděk Pour, Ph.D.; MD Laura Rosiñol, PhD; MUDr. Jan Straub; M.D. Alexander Suvorov; MD Carla Araujo; MUDr. Tomáš Pika; MD Katja C. Weisel; MD Vesselina Goranova-Marinova, PhD; MD Gianluca Gaidano, PhD; Heidi H. Gillenwater; Wee Joo Chng
Číslo abstraktu: 8509
Kategorie: Mnohočetný myelom

Poster

Palonosetron vs ondansetron: Prevention of chemotherapy-induced nausea and vomiting in pediatric patients in a multicycle study.

Autoři: as.MUDr. Edita Kabíčková, Ph.D.; M.D. Antonio Wachtel; Elena Basharova; Tulla Spinelli; Pierre Nicolas; Gabor Kovacs
Číslo abstraktu: 10077
Kategorie: Nádory dětského a adolescentního věku

Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.

Autoři: M.D. Charles S. Fuchs, MPH; Kei Muro; MUDr. Jiří Tomášek, Ph.D.; Eric Van Cutsem; Jae-Yong Cho, M.D., Ph.D.; Prof. M.D. Sang Cheul Oh; Prof. Dr. Howard Safran; M.D. György Bodoky, Ph.D.; M.D. Ian Chau; Yasuhiro Shimada; Dr. Filip Dumitru; MD Salah-Eddin Al-Batran; MD Rodolfo Passalacqua; Dr. Atsushi Ohtsu; MD Michael Emig; Prof. M.D. David R. Ferry, Ph.D.; Kumari Chandrawansa; Yanzhi Hsu, Ph.D.; Andreas Sashegyi, Ph.D.; Prof. MUDr. Hansjochen Wilke
Číslo abstraktu: 4028
Kategorie: Gastrointestinální nádory

Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study.

Autoři: Dr. Arvind (Nageshwara Vijaya) Dasari, MBBS; Prof. M.D. Alexandria T. Phan; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Edward M. Wolin; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski
Číslo abstraktu: 4104
Kategorie: Gastrointestinální nádory

Wilms’ tumor gene 1 (WT1) aberrations in testicular germ cell tumors (TGCTs).

Autoři: MUDr. Ludmila Boublíková, Ph.D.; Mgr. Violeta Bakardjieva-Mihaylova; Mgr. Karolina Škvárová Kramarzová, Ph.D.; Mgr. Daniela Kužílková; prof. MUDr. Tomáš Büchler, Ph.D.; MUDr. Pavel Dušek; MUDr. Marek Grega; MUDr. Blanka Rosová; Doc. MUDr. Zdeňka Vernerová, CSc.; MUDr. Petr Klézl; prof. MUDr. Roman Zachoval, Ph.D.; MUDr. Michal Pešl; MUDr. Marek Krolupper; Doc.MUDr. Martina Kubecová, Ph.D.; MUDr. Vladimíra Stáhalová; prof. MUDr. Marek Babjuk, CSc.; prof. MUDr. Jitka Abrahámová, DrSc.; prof. MUDr. Roman Kodet, CSc.; Prof.MUDr. Jan Trka, Ph.D.
Číslo abstraktu: 4534
Kategorie: Genitourinární nádory

Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.

Autoři: MD Brian I. Rini; prof. MUDr. Yoshihiko Tomita; prof. MUDr. Bohuslav Melichar, Ph.D.; MD Takeshi Ueda, Ph.D.; PD Dr. Viktor Grünwald (Gruenwald); MD Mayer N. Fishman, Ph.D.; Dr. Hirotsugu Uemura; Mototsugu Oya; Angel H. Bair; Glen Andrews; Dmitri Pavlov, Ph.D.; Dr. Eric Jonasch
Číslo abstraktu: 4545
Kategorie: Genitourinární nádory

Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.

Autoři: Paolo Grassi; Ludovic S. Doucet; Palma Giglione; PD Dr. Viktor Grünwald (Gruenwald); prof. MUDr. Bohuslav Melichar, Ph.D.; MD Luca Galli; Ugo De Giorgi; Annalisa Guida; Cinzia Ortega; Dr. Matteo Santoni; MD Aristotelis Bamias, PhD; Elena Verzoni; Dr. Andrea Necchi; Lisa Derosa; doc. MUDr. Hana Študentová, Ph.D.; Monica Pacifici; Filippo G. De Braud; Dr. Camillo Porta; MD Bernard J. Escudier; Dr. Giuseppe Procopio
Číslo abstraktu: 4550
Kategorie: Gastrointestinální nádory

Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.

Autoři: M.D. Georgios Gakis, F.E.B.U; M.D. Todd Matthew Morgan; M.D. Siamak Daneshmand; M.D. Kirk A. Keegan; M.D. Rebecca Helen Clayman; Johannes Mischinger; M.D. Harras B. Zaid; MUDr. Jan Hrbáček; M.D. Bedeir Ali-El-Dein; Sigolene Galland; MD Kola Olugbade; M.D. Michael Rink; Dr. Hans-Martin Fristche; M.D. Maximilian Burger; M.D. Sam Chang; prof. MUDr. Marek Babjuk, CSc.; Prof. M.D. George Niklaus Thalmann; Prof. M.D. Arnulf Stenzl; M.D. Jason Alexander Efstathiou, Ph.D.
Číslo abstraktu: 4568
Kategorie: Genitourinární nádory

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).

Autoři: Prof. Dr. med. Christian Jackisch; Roberto Hegg; M.D. Daniil Stroyakovskiy; MD Jin Seok Ahn; prof. MUDr. Bohuslav Melichar, Ph.D.; MD Shin-Cheh Chen; PharmD Aulde Crepelle-Flechais; Dominik Heinzmann; MD Mona Shing; Xavier B. Pivot
Číslo abstraktu: 585
Kategorie: Zhoubné nádory prsu

Development of a bispecific tetravalent CD33/CD3 TandAbfor the treatment of AML.

Autoři: Dr. Uwe Reusch; Kristina Ellwanger; Michael Weichel; Dr. Vera Molkenthin, Ph.D.; Judith A. Fox, Ph.D.; Dr. Stefan Knackmuss; Ivica Fucek; Erich Rajkovic; Eugene Zhukovsky; Jeanmarie Guenot, Ph.D.; Dr. Martin Treder
Číslo abstraktu: 7071
Kategorie: Maligní lymfomy a leukémie

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

Autoři: Meletios Athanasios Dimopoulos, MD; MD A. Keith Stewart; Prof. Dr. S. Vincent Rajkumar; MD Tamas Masszi, PhD; M.D. Albert Oriol; prof. MUDr. Roman Hájek, CSc.; MD Laura Rosiñol, PhD; MD David Samuel diCapua Siegel, PhD; Prof. M.D. Georgi Mihaylov, Ph.D.; MD Vesselina Goranova-Marinova, PhD; MD Péter Rajnics, Ph.D.; M.D. Alexander Suvorov; MD Ruben Niesvizky; MD Andrzej Jakubowiak, PhD; Prof. M.D. Jesús San Miguel, Ph.D.; Prof. MD Heinz Ludwig; MD Naseem Zojwalla; Prof. MD Philippe Moreau; MD Antonio P. Palumbo
Číslo abstraktu: 8525
Kategorie: Maligní lymfomy a leukémie

Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.

Autoři: Prof. MUDr. Marek Trněný, CSc.; MD Thierry Lamy; MD Jan Andrzej Walewski, Ph.D.; MUDr. David Belada, Ph.D.; prof. MUDr. Jiří Mayer, CSc.; Prof. M.D. John Radford; Wojciech Jurczak; MD Franck Morschhauser, PhD; Julia Alexeeva; prof. Simon A. Rule; Tsvetan Nikolov Biyukov; Meera Patturajan; Marie-Laure Casadebaig Bravo; Dr. José Cabecadas; Luca Arcaini
Číslo abstraktu: 8547
Kategorie: Maligní lymfomy a leukémie

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

Autoři: Sandra Van Schaeybroeck; Christian D. Rolfo; Elena Élez; Stephen Kelly; Jennifer Houlden; Linda Collins; Sharon Love; MD Thierry André; prof. Mark Lawler; Federica Di Nicolantonio; Margaret Grayson; Ing. Vlad Calin Popovici; Alberto Bardelli, Ph.D.; prof. Pierre-Laurent Puig; prof. Manuel Salto-Tellez; Tim Maughan, MA MB BS FRCP FRCR MD; Josep Tabernero, MD; Dr. Marc Peeters, PhD; Richard H. Wilson; prof. Mark R. Middleton
Číslo abstraktu: TPS3632
Kategorie: Kolorektální karcinom

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

Autoři: Nicholas J. Vogelzang; MD Tomasz M. Beer, F.A.C.P.; Prof. MUDr. Jiřina Bartůňková, DrSc.; MUDr. Rostislav Kuklík, MBA; Prof. Dr. Med. Kurt Miller; Prof. MD William K. Oh; Dr. Stephane Oudard; Prof. MUDr. Hardev S. Pandha, MB ChB (Birm), FRACP, FRCP, PhD, CSST; MD A. Oliver Sartor; Prof. MUDr. Radek Špíšek, Ph.D.; MD Niels Geert Borgstein; prof. MUDr. Winald R. Gerritsen
Číslo abstraktu: TPS5070
Kategorie: Genitourinární nádory

Publication-only abstracts

Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial).

Autoři: Christiane Thallinger; Prof. Dr. István Lang; MD Cvetka Grašič Kuhar; doc. MUDr. Rupert Bartsch; MD Christian F. Singer; prof. MUDr. Luboš Petruželka, CSc.; prof. MUDr. Bohuslav Melichar, Ph.D.; MD Regina Knittelfelder, Ph.D.; prof. MD Thomas Brodowicz; Prof. Dr. Christoph C. Zielinski
Číslo abstraktu: e11603
Kategorie: Zhoubné nádory prsu

Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors.

Autoři: prof. Wen Wee Ma, MBBS; MD Ik-Joo Chung, Ph.D.; Prof. Dr. István Lang; Dr. Tibor Csőszi; Dr. Miklos Wenczl; Dr. Antonio Cubillo; MD Jen-Shi Chen; MD Mark Wong; Joon Oh Park; Prof. MD Jun Suk Kim, Ph.D.; Kun-Ming Rau; prof. MUDr. Bohuslav Melichar, Ph.D.; Javier Gallego; MUDr. Martin Šmakal; Jaeyeon Kim; Dr. Eliel Bayever; Bruce Belanger; Navreet Dhindsa; Istvan Molnar; Bambang Adiwijaya
Číslo abstraktu: e13588
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie

Cetuximab plus chemotherapy as second line treatment of patient with metastatic colorectal cancer after failure of cetuximab containing regiment in first line: Single cancer center experience.

Autoři: MUDr. Michal Vočka, Ph.D.; RNDr. Ing. Bc. Libor Staněk, PCTM; prof. MUDr. Luboš Petruželka, CSc.
Číslo abstraktu: e14678
Kategorie: Kolorektální karcinom

Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.

Autoři: Dr. Arvind (Nageshwara Vijaya) Dasari, MBBS; Prof. M.D. Alexandria T. Phan; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Edward M. Wolin; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski
Číslo abstraktu: e15177
Kategorie: Gastrointestinální nádory

Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.

Autoři: Prof. M.D. Alexandria T. Phan; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Edward M. Wolin; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski
Číslo abstraktu: e15178
Kategorie: Gastrointestinální nádory

Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).

Autoři: MD Edward M. Wolin; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; Prof. M.D. Alexandria T. Phan; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski
Číslo abstraktu: e15180
Kategorie: Gastrointestinální nádory

Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).

Autoři: Prof. M.D. Alexandria T. Phan; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Edward M. Wolin; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski
Číslo abstraktu: e15181
Kategorie: Gastrointestinální nádory

Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.

Autoři: MD Edward M. Wolin; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; Prof. M.D. Alexandria T. Phan; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski
Číslo abstraktu: e15182
Kategorie: Gastrointestinální nádory

Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).

Autoři: Dr. Simron Singh, MD, MPH, FRCP(C); Roberto Buzzoni; Carlo Carnaghi; MD Nicola Fazio, Ph.D.; Prof. Dr. Marianne E. Pavel, M.D.; MD Edward M. Wolin; MUDr. Jiří Tomášek, Ph.D.; M.D. Markus Raderer; Dr. med. Harald Lahner; Du Hung Lam; Helene Cauwel; M.D. Juan W. Valle; Prof. M.D. Gianfranco Delle Fave; Eric Van Cutsem; Dr. MD Jonathan R. Strosberg; Dr. Margot Et Tesselaar; Yasuhiro Shimada; Do-Youn Oh; MD Matthew H. Kulke, MD; MD James C. Yao
Číslo abstraktu: e15197
Kategorie: Gastrointestinální nádory

Modified FOLFIRINOX as initial treatment of advanced pancreatic cancer: A single cancer center experience.

Autoři: MUDr. Michal Vočka, Ph.D.; prof. MUDr. Zdeněk Krška, CSc.; MUDr. David Hoskovec, Ph.D.; MUDr. Josef Hořejš; prof. MUDr. Luboš Petruželka, CSc.
Číslo abstraktu: e15228
Kategorie: Gastrointestinální nádory

Metastatic adeoid cystic carcinoma of the salivary gland.

Autoři: MUDr. Dagmar Brančíková, Ph.D.; MUDr. Markéta Protivánková; MUDr. Lenka Ostřížková; MUDr. Zdeněk Mechl, CSc.; MUDr. Radek Pejčoch
Číslo abstraktu: e17027
Kategorie: Nádory hlavy a krku